B2C Consumer App / Platform · vs · Publisher & Media Owner · B2B SaaS Provider
Hims & Hers vs WebMD
Structured technology and market comparison · 2026
Direct Feature Comparison
Hims & Hers · vs · WebMDConsumer telehealth platform with subscription-based treatment and fulfilment.
Digital health publisher with healthcare advertising and audience targeting assets.
Analyze all overlapping signals and tech stacks for Hims & Hers and WebMD
Compare mutual enterprise clients, monetization models, live market signals, and partner networks directly in the interactive Knowledge Graph.
Comparison Analysis
What is the main difference between Hims & Hers and WebMD?
When comparing Hims & Hers and WebMD, both platforms operate within the B2C Consumer App / Platform and Publisher & Media Owner · B2B SaaS Provider ecosystem. Hims & Hers is positioned as Consumer telehealth platform with subscription-based treatment and fulfilment, whereas WebMD focuses on Digital health publisher with healthcare advertising and audience targeting assets. Decision-makers evaluate both solutions when orchestrating their commercial monetization and technology stack.
What are the top alternatives to Hims & Hers and WebMD?
When evaluating Hims & Hers and WebMD, enterprise buyers also consider other platforms in B2C Consumer App / Platform and Publisher & Media Owner · B2B SaaS Provider. You can discover the full competitive landscape and evaluate other alternatives by viewing their respective footprint profiles on Polaris7.
How do the corporate scale, structure, and headquarters of Hims & Hers and WebMD compare?
Hims & Hers is headquartered in United States (founded in 2017) with 1,001–5,000 employees. WebMD is based in United States (founded in 1998) with 1,001–5,000 employees. Complete ownership, subsidiary trees, and corporate affiliations are documented across Polaris7.
Market Signals
Recent Market Signals & Activity: Hims & Hers vs WebMD
Documented market movements, strategic partnerships, product releases, and regulatory developments mapped across Polaris7.
Hims & Hers
Recent Signals
- ·SEC APIfinancials
8-K Financial Filing Analysis for Hims & Hers (2026-10-07)
Hims & Hers Health, Inc. announced the appointment of Jonathan M. Franklin as Chief Accounting Officer and Principal Accounting Officer, effective October 9, 2026. Mr. Franklin succeeds Irene Becklund, who previously resigned but will remain with the company in an advisory capacity through July 10, 2027, ensuring an orderly transition. Prior to joining Hims & Hers, Franklin served as Vice President, Corporate Controller at Rivian Automotive and spent over 15 years in public accounting at PwC. His compensation package includes an annual base salary of $425,000, a $150,000 signing bonus, an annual target bonus of 50%, and an initial grant of $3,000,000 in restricted stock units (RSUs) vesting over four years.
- Jonathan M. Franklin appointed Chief Accounting Officer and Principal Accounting Officer effective October 9, 2026, succeeding Irene Becklund.
- Compensation includes an annual base salary of $425,000, a $150,000 signing bonus, a 50% target discretionary bonus, and $3,000,000 in equity awards (RSUs) vesting over 4 years.
- Outgoing Principal Accounting Officer Irene Becklund will serve under an advisory agreement through July 10, 2027.
- ·PR Newswire: Advertising & MarketingPrivacy
Hims & Hers Securities Class Action Deadline Nov 2, 2026
Robbins Geller Rudman & Dowd LLP has announced a securities class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS), alleging violations of the Securities Exchange Act. The lawsuit, captioned Velanki v. Hims & Hers Health, Inc., is pending in the Northern District of California. It claims that the company made false statements and failed to disclose that it shared consumers' sensitive health information with third-party advertising platforms like Meta and Snap, and that it misled consumers about billing practices. Following an FTC lawsuit filed on July 29, 2026, the company's stock dropped nearly 15%. Investors who purchased securities between August 4, 2025 and July 29, 2026 have until November 2, 2026, to seek lead plaintiff appointment under the Private Securities Litigation Reform Act.
- FTC filed a lawsuit against Hims & Hers on July 29, 2026, alleging sharing of sensitive health data with advertising platforms like Meta and Snap, and misleading billing.
- Hims & Hers stock declined nearly 15% following the FTC announcement.
- Robbins Geller Rudman & Dowd LLP filed a class action lawsuit (Velanki v. Hims & Hers Health, Inc.) in the Northern District of California.
- ·SEC APIfinancials
10-Q Financial Filing Analysis for Hims & Hers (2026-08-10)
Hims & Hers reported Q2 2026 revenue of $753.2 million, up 38% year-over-year, and six-month revenue of $1.36 billion (+20% YoY), driven by strong expansion in the Hers brand and international growth from acquisitions including Eucalyptus. However, the company experienced a GAAP net loss of $86.3 million for Q2 2026 (compared to net income of $42.5 million in Q2 2025), primarily impacted by a strategic transition in its U.S. GLP-1 weight loss business, non-recurring restructuring charges, increased fulfillment costs from shorter shipping cadences, and a $60 million FTC legal contingency accrual.
- Q2 2026 total revenue reached $753.21 million (+38% YoY) with ending subscribers expanding 19% YoY to 2.89 million.
- GAAP net loss was $86.29 million for Q2 2026, down from net income of $42.51 million in Q2 2025, while Adjusted EBITDA stood at $60.32 million.
- Recorded a $60.0 million legal contingency accrual related to an FTC and multi-state consumer protection lawsuit regarding subscription and cancellation practices.
WebMD
Recent Signals
No recent market signals documented for WebMD in the current tracking window.
Compare their exact ecosystem overlaps.
Explore all deep relationships in Polaris7. Discover exactly which mutual clients, integrated technologies, and overlapping partners Hims & Hers and WebMD share across the market ecosystem.
Unlock full capability matrix, client overlaps & technology stacks